Genmab A/S: Epkinly RR DLBCL DLBCL-4 trial success derisks c.$0.7bn peak sales indication, and has +ve read to 1L data in H2

Research evidence excerpt

Genmab A/S: Epkinly RR DLBCL DLBCL-4 trial success derisks c.$0.7bn peak sales indication, and has +ve read to 1L data in H2

Equity Research

European Pharmaceuticals, Biotechnology & Life Sciences

30 June 2026

Genmab A/S

Epkinly RR DLBCL DLBCL-4 trial

success derisks c.$0.7bn peak First Look

GMAB.CO/GMAB DC OVERWEIGHTsales indication, and has +ve read

European Pharmaceuticals,

Biotechnology & Life NEUTRAL

Sciencesto 1L data in H2

Price Target DKK 2500.00

Price (29-Jun-26) DKK 1718.50Epkinly CD3xCD20 + len, EPCORE RR DLBCL-4 trial succeeds,

40% PFS benefit on Primary, de-risks c.$0.7bn peak sales opp, PotentialSource: Bloomberg,Upside/DownsideBarclays Research +45.5%

and has +ve read to 1L readout in H2, which has $bb peak

potential. European Pharmaceuticals,

Biotechnology & Life Sciences

James Gordon

Last night, Genmab/ Abbvie (covered by Emily Field) reported positive topline results from +44 (0)20 7116 2784

the Phase 3 EPCORE DLBCL-4 trial evaluating fixed‑duration Epkinly + lenalidomide james.gordon@barclays.com

vs. SoC R-GemOx (rituximab plus gemcitabine plus oxaliplatin), in adult patients with r/ Barclays, UK

rDLBCL who received at least one prior line of treatment. The study met its primary Yihan Li, PhD

endpoint, demonstrating a statistically significant and clinically meaningful improvement +44 (0)20 3555 3563

in PFS with a chemotherapy-free combination treatment regimen. The combination reduced yihan.li@barclays.com

the risk of progression or death by 60% (HR 0.40 [95% CI 0.30–0.55]) under US censoring rules Barclays, UK

and 56% (HR 0.44 [95% CI 0.33–0.60]) under OUS censoring, both with p<0.0001. Note the Sidhartha Modi

release did not include a comment on Overall Survival benefit (a key secondary endpoint), a +91 (0)22 6175 1326